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Abstract
Bacterial contamination of blood components such as ex vivo-stored platelets is a major safety risk in transfusion medicine. We have recently
shown that synthetic antimicrobial peptides named PD1–PD4 derived from the thrombin-induced human platelet-derived antimicrobial
proteins, and repeats of Arg-Trp (RW1–RW5) demonstrate microbicidal activity against selected bacteria and viruses. In the present study,
we selected PD3, PD4, RW2, RW3 and RW4 and evaluated each individual peptide and their various combinations to see whether the
cocktail regimen enhances the antimicrobial activity above and over the individual peptides. Stored platelet or plasma samples spiked with
known titres of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae and Bacillus
cereus were treated with either individual peptides or with peptides in various combinations. Analyses revealed that individual peptides show
moderate microbicidal activity (10- to 100-fold reduction) against the tested bacteria relative to their combined regimen. The peptide
combinations (RW2 + RW4, RW2 + RW3 + RW4 and PD4 + RW3 + RW4) on the other hand enhanced the microbicidal activity
(c.10 000-fold reduction) and revealed a minimal inhibitory concentration of 5 lM. Time-kill kinetics indicated that these three peptide
combinations exhibited enhanced antimicrobial activity bringing about a 100-fold reduction of bacterial titres within 20 min of incubation.
The present study therefore demonstrates the synergistic effect of antimicrobial peptides when used in combinations and provides a
proof-of-concept of its potential application as a molecular tool towards pathogen reduction and further extends the possibility of using
peptide combinatorial therapeutics as broad-spectrum antibiotics or as alternatives to combat drug-resistant bacteria.
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Introduction
Antibiotic misuse and overuse have led to the emergence of
multiple antibiotic-resistant strains [1], which necessitated the
need for new classes of antimicrobial agents. Natural and
synthetic antimicrobial peptides (AMPs) are gaining consider-
able attention because of their novel drug targets and the low
frequency of developing resistance to the AMPs [2,3]. These
peptides are 8–50 amino acids in length and mostly have
positive net charge, though anionic AMPs also exist [3–5]. The
exact mechanism of action of AMPs has not been fully
understood. However, extensive studies on the mode of
action of cationic AMPs have shown that positively charged
peptides interact with negatively charged membranes, thereby
causing increased permeability of the membrane and eventually
leading to bacterial cell death [3–5]. Development of resis-
tance to AMPs may occur, but to a lesser degree as it may
require alterations in the lipid composition of the membrane
of microorganisms [6].
Naturally occurring AMPs are components of the innate
defence mechanism of most life forms [6–8]. Cathelicidins and
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defensins are the best-characterized peptides among the host
defence peptides [7–9]. Platelets liberate platelet microbicidal
proteins (PMPs) when activated, thereby contributing to the
host defence against infection. PMPs from thrombin-induced
rabbit, and human platelets, also called the kinocidins (hPF-4),
were isolated and characterized and were shown to have
potent microbicidal activity against pathogens of the blood-
stream, such as Staphylococcus aureus, Streptococcus viridans,
Escherichia coli, Candida albicans and Cryptococcus neoformans
[10–16].
Short synthetic peptides containing Arg (R) and Trp (W)
residues have been shown to display significant antimicrobial
activity and low cytotoxic activity [17–19]. Longer chains of
RW repeats are effective against both gram-positive and
gram-negative bacteria though the peptide chain length
increases the haemolytic activity. Positively charged Arg
residue interacts with the bacterial membrane through elec-
trostatic attraction whereas the non-polar Trp residue inter-
acts with the lipid bilayer through hydrophobic interactions.
These two activities in a single peptide aid the peptide to
interact with the bacterial membrane, which ultimately results
in membrane destabilization and pore formation, leading to
bacterial cell death [17–20].
Contamination of ex vivo stored platelets in bags at room
temperature mostly by bacteria, and rarely by viruses, and
parasites is a safety issue in transfusion medicine. Development
of methods to reduce the growth of medically important
bacteria in platelets would enhance the safety of these
transfusion products. We have recently demonstrated that
peptides derived from thrombin-induced human platelet
antimicrobial proteins (PD1–PD4) and Arg-Trp (RW1–RW5)
repeats exhibit microbicidal activity against bacteria and
vaccinia virus in plasma and in platelet concentrates [21,22].
In this study we have selected PD3, PD4, RW2, RW3 and
RW4 peptides and tested their efficacy either individually or in
combinations to see whether the combined regimen enhances
the antimicrobial activity of these peptides.
Materials and Methods
Bacterial strains and growth conditions
Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis
ATCC 35983, E. coli ATCC 700928, Pseudomonas aeruginosa
ATCC 12121, Klebsiella pneumoniae ATCC 10031 and Bacillus
cereus ATCC 11778 were used in this study. All bacterial
strains were grown routinely at 37°C on nutrient agar or
Luria–Bertani (LB) broth (Mediatech Inc, Herndon, VA, USA).
For long-term storage, all strains were stored in tryptic soy
broth with 10% glycerol at 80°C.
Peptide synthesis
Antimicrobial peptides described in this study were synthe-
sized at the Center for Biologics Evaluation and Research, the
Food and Drug Administration core facility, as previously
described [21,22]. PMP-1 consensus sequence-derived pep-
tides (PD3 and PD4) were 15 amino acids in length and
Arg-Trp peptides (RW2, RW3 and RW4) were two to four
repeats of Arg-Trp amino acids (Table 1) [21,22]. Peptides
were all reconstituted in PBS, pH 7.4 (Invitrogen, Carlsbad,
CA, USA) and stock solutions were made to 10 mM concen-
tration in the same buffer.
Antibacterial assays
The test bacteria mentioned in the Materials and Methods
were grown in LB broth to mid-logarithmic phase and
centrifuged at 3000 g and resuspended in 1 9 PBS. Human
plasma and platelet samples were acquired from the National
Institutes of Health Blood Bank (Bethesda, MD, USA). All
antibacterial assays were performed as described previously
with slight modifications [21–24]. Approximately 106 CFU/mL
(0.1 mL) of each bacterial strain was spiked into 0.9 mL of
plasma or platelets and incubated with each PD and RW
peptide individually or in different combination cocktails as
shown in Table 2. The treated samples and controls were all
incubated at room temperature for 90 min on an orbital
shaker. At the end of the 90-min exposure period, 0.1 mL of
the suspension was plated on nutrient agar plates and the
colonies were counted after 18–24 h of incubation. Bacteri-
cidal activity of the peptides and their combinations were
measured by log-reduction by viable bacteria. Experiments
were repeated at least five times.
Minimal inhibitory concentration analyses
Mid-logarithmic phase cultures of bacteria grown in LB broth
were centrifuged at 3000 g and resuspended in 1 9 PBS [21–
24]. Approximately 106 CFU/mL (50 lL) of each bacterial
strain was incubated with 50 lL of serial, double-fold dilutions
of the four different combination cocktails: RW2 + RW4,
RW2 + RW3 + RW4, PD3 + RW3 + RW4 and PD4 + RW3
+ RW4. The peptide serial dilutions were calibrated such that
upon adding the bacterial suspension the final concentration of
TABLE 1. Sequence of antimicrobial PD and RW peptides
used in the study
S. No. Peptide Sequence
1 PD3 KNGRKLCLDLQAALY
2 PD4 AALYKKKIIKKLLES
3 RW2 RWRW
4 RW3 RWRWRW
5 RW4 RWRWRWRW
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each peptide combination in the 0.1-mL sample series were
10 lM, 5 lM, 2.5 lM, 1.25 lM and 0.6 lM. Bacterial titres
were estimated at the end of incubation by colony counting as
described above.
Time-kill assay
Kinetics of the bactericidal activity of the peptides were
evaluated both for single peptides and for the combinations
using the time-kill assay on two bacterial species, S. aureus and
E. coli representing gram-positive and gram-negative bacteria
[23–26]. These two bacterial cultures were treated with either
the individual peptides or combinations of PD4, RW2, RW3 and
RW4 peptides at 10 lM concentrations. Samples were col-
lected and plated at 0, 20 min, 60 min, 90 min and 120 min of
incubation at 37°C. Positive controls for the assay included
ampicillin for S. aureus and Polymyxin B for E. coli. Bacterial
cultures without any peptidewere included as negative controls.
Transmission electron microscopy
As above, the same two bacterial species, S. aureus and E. coli,
were selected for this study. Log-phase cultures of bacteria
were centrifuged and the bacterial pellet was washed three
times and resuspended in PBS. Ten-fold serial dilutions of the
S. aureus and E. coli cultures were incubated with a 10 lM
concentration of each peptide or PBS for 1 h. The bacteria–
peptide complex was washed three times with PBS and the
samples were fixed in 2% glutaraldehyde and 2% paraformal-
dehyde in PBS, pH 7.3 for 3–24 h. The samples were then
further fixed in 1% osmium tetroxide in PBS. Finally, the
samples were dehydrated before embedding in resin. After
microtomy, the samples were transferred to copper grids and
stained with uranyl acetate and lead citrate. Sections were
observed by using a Zeiss 912 transmission electron micro-
scope and images were captured digitally. Test samples
without any peptides were included as controls.
Statistics
Assays described here were performed at least four times
independently. Mean values  standard deviation (SD) was
calculated using MICROSOFT EXCEL. Statistical analyses were
performed using Student’s t test and values were considered
significant when p <0.05.
Results
Peptides in combination exhibit enhanced microbicidal
activity
Analyses of PD3, PD4, RW2, RW3 and RW4 peptides both
individually and in various combinations against bacteria spiked
in plasma revealed that individually each peptide was able to
bring about a 10- to 100-fold reduction in bacterial titres.
Comparatively the RW peptides exhibited a higher antimicro-
bial activity than the PD peptides (Fig. 1). Among the various
combinations, the RW2 + RW4, RW2 + RW3 + RW4,
PD3 + RW3 + RW4 and PD4 + RW3 + RW4 were the
most potent ones in bringing about ≥1000-fold reduction in
bacterial titres and in some cases almost about a 10 000-fold
reduction. A distinct variability in action of the combined
peptides against the different bacteria was also observed
(Fig. 1).
Additional evaluation of antimicrobial activity of the above
peptides in spiked platelets revealed that the peptides were
equally active in this biological matrix. The peptide combina-
tions, RW2 + RW4, RW2 + RW3 + RW4, PD3 + RW3 +
RW4 and PD4 + RW3 + RW4 demonstrated similar antimi-
crobial activities to that observed in the case of spiked plasma,
with a 1000- to 10 000-fold reduction in bacterial titres.
Though the antimicrobial activity in spiked-platelets was
slightly lower than the peptide activity in plasma, the difference
was not significant.
Four most effective peptide combinations against all tested
bacteria
None of the PD and RW peptides were individually active in
affecting a ≥1000-fold reduction in bacterial titres against all six
tested bacteria, so we tested whether this could be achieved
by combining one or more peptides in cocktail combinations.
Our analyses revealed that of the 11 different cocktail
combinations, four peptide combinations: (i) RW2 + RW4,
(ii) RW2 + RW3 + RW4, (iii) PD3 + RW3 + RW4 and (iv)
PD4 + RW3 + RW4, were the most potent in bringing about
a 1000- to 10 000-fold reduction of bacterial titres (Fig. 2). In
addition there were two other peptide combinations
(RW2 + RW3 and RW3 + RW4) that were effective in
bringing about at least a 10- to 10 000-fold reduction against
TABLE 2. Various combinations of peptides that were tested
for antibacterial activity
S. No. Peptides and combinations
1 Control (bacteria without peptides)
2 PD3
3 PD4
4 RW2
5 RW3
6 RW4
7 PD3 + PD4
8 RW2 + RW3
9 RW3 + RW4
10 RW2 + RW4
11 RW2 + RW3 + RW4
12 PD3 + RW3
13 PD3 + RW4
14 PD4 + RW3
15 PD4 + RW4
16 PD3 + RW3 + RW4
17 PD4 + RW3 + RW4
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the six tested bacteria (Fig. 2). Certain combinations, such as
PD3 with RW3 or RW4 and PD4 with RW3 or RW4 did not
exhibit any significant increase in microbicidal activity when
compared with individual activity of the peptides (Fig. 2).
Combined peptides exhibit a MIC of 5 lM
Once it was evident that the peptide combinations
RW2 + RW4, RW2 + RW3 + RW4, PD3 + RW3 + RW4
and PD4 + RW3 + RW4 were the most potent, we evaluated
the MIC of these combinations that would bring about at least
a ≥1000-fold reduction of all the six tested bacteria. Serial,
double-fold dilutions of the cocktail peptide combinations
were prepared (range: 10–0.6 lM) and tested against all six
bacteria. Our analysis revealed that of the four tested peptide
combinations, three: (i) RW2 + RW4, (ii) RW2 + RW3 +
RW4, and (iii) PD4 + RW3 + RW4, were effective even at
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FIG. 1. Illustration of antimicrobial activity of PD and RW peptides and their combinations. Plasma (striped columns) and platelet (filled columns)
samples were spiked with six different medically important bacteria and co-incubated with either PD or RW peptides individually or in combinations
at 10 lM concentrations. Bacterial titres were estimated by plating a fixed volume of the incubation mix and performing a colony count. Samples
without any peptides but spiked with individual bacterial strain were treated as controls. The peptide combinations demonstrate enhanced
microbicidal activity against most of the bacteria tested in both plasma and platelet samples. Results are presented as mean  SD. (**p <0.0001,
*p <0.001).
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5 lM concentration and brought about a ≥1000-fold reduction
of all six tested bacteria (Fig. 3). The PD3 + RW3 + RW4
combination at 5 lM concentration was effective in bringing
about only a 2-log reduction. Lower dilutions of the various
combinations on the other hand were selectively effective
against some bacteria and resulted in c.10- to 1000-fold
reduction of bacterial titres (Fig. 3).
Time-kill kinetics reveals a rapid killing potential of the
peptide combinations
The results so far indicated that the combined peptides were
active in both plasma and platelets with three of the
combinations being most potent with an MIC of 5 lM. Hence,
it was critical to further evaluate the rapidity at which these
peptide combinations brought about the microbicidal effects;
for this reason the time-kill assay was performed at various
time points between 0 and 120 min of peptide treatment on
two selected bacterial species, S. aureus and E. coli represent-
ing gram-positive and gram-negative bacteria, respectively.
Findings from this assay revealed that all three peptide
combinations were effective the instant they were added to
the bacterial culture resulting in c.ten-fold reduction in
bacterial numbers of both S. aureus and E. coli and, by
20 min the combined treatment resulted in a 100-fold
reduction of bacterial titres (Fig. 4). By the end of 90-min
incubation, the three peptide combinations effectively resulted
in c.1000- to 10 000-fold reduction of bacterial titres. Inter-
estingly, individual peptide treatments took 60–90 min to bring
about a c.10- to 100-fold reduction in numbers of S. aureus and
E. coli (Fig. 4).
Electron microscopy reveals structural changes in
peptide-treated bacteria
To evaluate structural changes elicited by the peptides on
bacteria two bacterial species were selected, S. aureus and
E. coli representing gram-positive and gram-negative bacteria,
and treated individually with PD4, RW2, RW3 or RW4
peptides. Samples were analysed using a Zeiss 912 transmis-
sion electron microscope and images were captured. Results
indicated that all four peptides were able to bring about a
multitude of structural changes in the treated bacteria (Fig. 5).
PD4 treatment resulted in loss of structural integrity,
ballooning of cells, loss of cytoplasmic content and cytoplasmic
granulation (Fig. 5). Similarly, treatment with RW2, RW3 or
RW4 resulted in all of the above cytopathic effects both in
S. aureus and E. coli. Additionally, certain bacterial cells also
exhibited formation of bulbar structures or protrusions from
the cell surface (Fig. 5).
Discussion
We had previously shown that PD and RW peptides exhibit
antimicrobial properties against bacteria and vaccinia virus
spiked in blood components such as plasma and platelets
[21,22]. Our previous findings indicated that there was no
single peptide that was active against all bacteria in bringing
about a ≥1000-fold reduction in bacterial titres [21,22]. Hence,
we theorized that perhaps by combining these individual
peptides, as a cocktail, an additive or synergistic effect could be
imparted to the cocktail mixture that could then have a
broad-spectrum antimicrobial effect and bring about a signif-
icant reduction in bacterial titres. In the present study we
demonstrate that by testing 11 different peptide combinations
of PD3, PD4, RW2, RW3 and RW4 we were able to identify
the three most potent peptide combinations as RW2 + RW4,
RW2 + RW3 + RW4 and PD4 + RW3 + RW4. These three
cocktails were able to bring about c.10 000-fold reduction in
the bacterial titres of all six bacteria tested, which was at least
10- to 100-fold higher than the action of individual peptides
acting alone.
Combination therapy, which uses a mixture of two drugs,
has been extensively used to treat many infectious diseases
[8,27]. More recently, experimental evidence is gaining
importance with regards to combination therapy in controlling
bacterial infections as well [23,25,28,29]. So far, there have
been a few reports that demonstrate the efficacy of combi-
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FIG. 2. Analyses of antimicrobial activity of combinatorial peptides
against various bacteria. The most potent combinations are
RW2 + RW4, RW2 + RW3 + RW4, PD3 + RW3 + RW4 and
PD4 + RW3 + RW4 exhibiting a 1000- to 10 000-fold reduction of
bacterial titres. Also note two other peptide combinations
(RW2 + RW3 and RW3 + RW4) that effectively resulted in a 10-
to 10 000-fold reduction of the six tested bacteria.
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nation therapy using AMPs in combination with a conventional
antibiotic [23,27,28,30]. Such studies have clearly demon-
strated the enhanced effectiveness of the combined therapy
over single peptide or drug treatment especially for combating
drug-resistant bacterial strains or other hard-to-treat scenar-
ios such as persister cells [23,25,27,30]. Chen et al. [30] had
elegantly demonstrated that by combining peptides RW2,
RW3 and RW4 with ampicillin or ofloxacin, a synergistic
increase in microbicidal activity against persister cells in
biofilms was achieved. Furthermore, it was observed that
even if the peptides did not directly kill the bacteria, the
peptide treatment itself increased the susceptibility of the bac-
teria to both antibiotics. Similarly, other studies have reported
synergistic effects of AMPs that enhance or potentiate
susceptibility of microorganisms that were resistant to a
previously known drug or antibiotic. Findings from these
studies included Pseudomonas susceptibility to multiple
antibiotics, increase in therapeutic efficacy of miltefosine for
treating experimental leishmaniasis or enhanced synergistic
effect of AMPs against gram-positive bacteria [23,27,28]. The
present study provides further advancement of or an alternative
to the above scenarios and suggests that by combining various
AMPs as a mode of treatment, the microbicidal potential of
some of the individual peptides could be enhanced. An additional
advantage of combinatorial therapy is the lower minimal
inhibitory concentration or the lower dose requirement of
drug/peptides to bring about a significant treatment effect.
Our findings also present for the first time visual evidence
of the membrane-damaging effects of PD and RW peptides on
bacteria such as S. aureus and E. coli by means of transmission
electron microscopy. Though the cytopathic effects of PD and
RW peptides are not peptide-specific, they do indicate a
broader mode of action that encompasses effects such as loss
of structural integrity, ballooning of cells, loss of cytoplasmic
content, cytoplasmic granulation, and formation of bulbar
structures or protrusions from the cell surface of bacteria.
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FIG. 3. Demonstration of MIC of four selected peptide combinations based on their potent action. Serial two-fold dilutions of the peptide
combinations were carried out with final concentration ranging among 10, 5, 2.5, 1.25 and 0.6 lM and incubated with the respective bacteria. As
illustrated in the figure, peptide combinations RW2 + RW4, RW2 + RW3 + RW4, and PD4 + RW3 + RW4 were effective even at 5 lM
concentration and brought about a ≥1000-fold reduction of all six tested bacteria. The PD3 + RW3 + RW4 combination, however, was effective in
bringing about only a 2-log reduction at 5 lM concentration.
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Antimicrobial peptides have been reported to control
infections in various biological situations. Attempting to further
extend the varied application of AMPs the present study
demonstrates a proof-of-concept of the potential applicability
of these AMPs as molecular tools for pathogen reduction in
stored blood components against common bacterial contam-
inants. This is a first step in moving towards preclinical
evaluation of these peptides and their combinations in an
appropriate small animal model.
In conclusion, our findings demonstrate that by combining
the PD and RW peptides the following advantages can be
clearly achieved: (i) a broad-spectrum antimicrobial activity, (ii)
increased microbicidal activity in terms of fold reduction of
bacteria, (iii) lower MIC of the cocktail AMPs, and (iv) much
more rapid time-kill kinetics. Using our studies as a model,
similar synergistic AMP combinations may be designed using
other novel peptides and/or antibiotics to test difficult-to-treat
situations. Such combinations may result in the discovery of more
potent combinations of drugs that exhibit a broad-spectrum
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FIG. 4. Illustration of time-kill kinetics of three most potent peptide
combinations. Log-phase cultures of two bacterial species, Staphylo-
coccus aureus and Escherichia coli representing gram-positive and
gram-negative bacteria, were treated with peptide combinations at a
concentration of 10 lM and bacterial numbers were estimated at
time-points 0–120 min. As observed in the figure the peptide
combinations exhibited enhanced antimicrobial activity resulting in a
100- and 1000-fold reduction of bacterial titres within 20 and 60 min
of incubation, respectively.
FIG. 5. Transmission electron microscopy to illustrate the effects of
peptide treatment on bacteria. Structural changes elicited by the
peptides on bacteria were evaluated on two bacterial species,
Staphylococcus aureus and Escherichia coli representing gram-positive
and gram-negative bacteria that were treated individually with PD4,
RW2, RW3 or RW4 peptides. Controls included bacteria without
peptide treatment and electron microscopy analysis reveals a normal
morphology and structural integrity of both Staphylococcus aureus and
Escherichia coli cells. Peptide treatment on the other hand revealed a
multitude of structural changes in the treated bacteria such as loss of
structural integrity, ballooning of cells, loss of cytoplasmic content, and
cytoplasmic granulation. Certain bacterial cells also exhibited forma-
tion of bulbar structures or protrusions from the cell surface. Scale:
500 nm.
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activity not just against bacteria but also against viruses, fungi and
parasites.
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